Description
Kayaclav 457 mg/5 mL – Co-Amoxiclave is a ready-to-use oral suspension formulated with 457 mg of amoxicillin and 5 mg of clavulanate potassium per 5 mL. This combination enhances antibacterial efficacy by overcoming beta-lactamase resistance, making it suitable for treating various infections, including respiratory tract infections, ear infections, and skin infections. The dry powder formulation allows for easy preparation and ensures accurate dosing.
Key Benefits:
- Effective Against Resistant Bacteria: The clavulanate component protects amoxicillin from degradation, ensuring broader antibacterial coverage.
- Convenient Dosage Form: Designed for easy administration, especially in pediatric patients who may have difficulty swallowing tablets.
- Versatile Use: Ideal for treating a range of bacterial infections.
Dosage: Follow your healthcare provider’s instructions regarding the preparation, dosage, and duration of treatment.
Choose Kayaclav 457 mg/5 mL – Co-Amoxiclave Oral Suspension for reliable and effective antibacterial treatment.
